Prednisone
- Generic Name
- Prednisone
- Brand Names
- Deltasone, Rayos, Winpred
- Drug Type
- Small Molecule
- Chemical Formula
- C21H26O5
- CAS Number
- 53-03-2
- Unique Ingredient Identifier
- VB0R961HZT
- Background
A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.
Prednisone was granted FDA approval on 21 February 1955.
- Indication
Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.
- Associated Conditions
- Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis
- Associated Therapies
- Palliative Treatment
Twice Weekly Steroids and Exercise as Therapy for DMD
- Conditions
- Interventions
- First Posted Date
- 2020-03-26
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 89
- Registration Number
- NCT04322357
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis
- First Posted Date
- 2020-03-12
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 42
- Registration Number
- NCT04305145
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATL)
- Conditions
- Interventions
- First Posted Date
- 2020-03-09
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT04301076
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, United States
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
- Conditions
- Interventions
- First Posted Date
- 2020-03-09
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 142
- Registration Number
- NCT04300556
- Locations
- 🇺🇸
Chattanooga's Program In Women's Oncology, Chattanooga, Tennessee, United States
🇺🇸Arizona Clinical Research Center - Hunt - PPDS, Tucson, Arizona, United States
🇺🇸University of Arkansas For Medical Sciences, Little Rock, Arkansas, United States
Study Evaluating Sodium Selenite in Combination With Abiraterone in Castrate Resistant Prostate Cancer Progressing on Abiraterone
- Conditions
- Interventions
- First Posted Date
- 2020-03-05
- Last Posted Date
- 2021-08-12
- Lead Sponsor
- Stanford University
- Registration Number
- NCT04296578
Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-02-13
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 7
- Registration Number
- NCT04267887
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-02-10
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 28
- Registration Number
- NCT04262154
- Locations
- 🇺🇸
Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Commack (Limited Protocol Activities), Commack, New York, United States
🇺🇸Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States
Single and Multiple Ascending Dose Study of CORT113176 in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2020-01-30
- Last Posted Date
- 2022-02-01
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 110
- Registration Number
- NCT04249323
- Locations
- 🇬🇧
Quotient Sciences, Ruddington, Nottingham, United Kingdom
Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Untreated Aggressive Large B-cell Lymphoma
- Conditions
- Aggressive Non-Hodgkin LymphomaALK-Positive Large B-Cell LymphomaDiffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedEBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 RearrangementsHigh Grade B-Cell Lymphoma, Not Otherwise SpecifiedPrimary Mediastinal Large B-Cell LymphomaT-Cell/Histiocyte-Rich Large B-Cell LymphomaGray-Zone Lymphoma
- Interventions
- Drug: Polatuzumab VedotinBiological: RituximabDrug: PrednisoneDrug: EtoposideDrug: DoxorubicinDrug: CyclophosphamideProcedure: Multigated Acquisition ScanBiological: GlofitamabProcedure: EchocardiographyProcedure: FDG-Positron Emission TomographyProcedure: Computed TomographyProcedure: Bone Marrow BiopsyProcedure: Biospecimen CollectionProcedure: Bone Marrow Aspiration
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 56
- Registration Number
- NCT04231877
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
A Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis
- Conditions
- Interventions
- First Posted Date
- 2020-01-09
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 271
- Registration Number
- NCT04221477
- Locations
- 🇺🇸
North Shore University Hospital, Manhasset, New York, United States
🇺🇸University of Texas Southwestern, Dallas, Texas, United States
🇩🇪Universitaetsmedizin Johannes Gutenberg; Rheumatologie, Mainz, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.